Phathom Pharmaceuticals Surges to 157th Most Traded Stock with $502 Million Turnover

On June 6, 2025, Phathom Pharmaceuticals Inc. (PHAT) experienced a significant surge in trading volume, with a turnover of $502 million, marking a 1,682.69% increase from the previous day. This substantial rise in trading volume positioned Phathom as the 157th most traded stock of the day, reflecting a 90.19% increase in its stock price.

The surge in Phathom's stock price can be attributed to the U.S. Food and Drug Administration's (FDA) approval of the company's Citizen Petition regarding the expiration date of new chemical entities. This approval granted Phathom's Voquezna tablets a 10-year New Chemical Entity (NCE) exclusivity period, ensuring the drug's standalone tablets benefit from extended market protection until 2032.

This exclusivity period is a significant milestone for Phathom, as it secures the company's market position and enhances investor confidence. The FDA's decision to amend the exclusivity status for Voquezna, one of Phathom's key products, has fueled a sharp rise in the stock’s value, reflecting the market's positive response to the news.

Phathom Pharmaceuticals reported net revenues of $28.5 million for the first quarter of 2025, with a notable increase in filled prescriptions. The company's strong cash position, with $212 million in cash and cash equivalents, positions it well to achieve profitability by 2026 without additional financing. Phathom has successfully launched its drug, Vuesna, achieving an annualized run rate of $120 million in net revenues within the first 18 months.

Despite these positive developments, Phathom faces potential supply disruptions for one of its H. Pylori combination packs and a shift in volume toward cash pay, which may impact revenues. The company is also halting its broadcast television promotion due to lower ROI and deferring its phase 2 eosinophilic esophagitis study, which could affect its pediatric extension strategies. Additionally, there is uncertainty regarding the FDA's decision on the company's citizen's petition, which is critical for its exclusivity timeline and could affect future market dynamics.